EP2755993 - PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 14.09.2018 Database last updated on 24.08.2024 | |
Former | The patent has been granted Status updated on 06.10.2017 | ||
Former | Grant of patent is intended Status updated on 01.09.2017 | ||
Former | Examination is in progress Status updated on 22.08.2017 | ||
Former | Grant of patent is intended Status updated on 20.03.2017 | ||
Former | Examination is in progress Status updated on 23.01.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states The U.S.A. as represented by the Secretary, Department of Health and Human Services National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, MD 20892-7660 / US | [2017/45] |
Former [2014/30] | For all designated states The U.S.A. as represented by the Secretary, Department of Health and Human Services National Institues of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, MD 20892-7660 / US | Inventor(s) | 01 /
PASTAN, Ira, H. 11710 Beall Mountain Road Potomac, MD 20854 / US | 02 /
ONDA, Masanori 320 Lorraine Drive Rockville, MD 20852 / US | 03 /
LIU, Wenhai 40 Cornerstone Court Suite 24 Plantsville, CT 06479 / US | [2014/30] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2017/45] |
Former [2014/30] | Vossius & Partner Siebertstrasse 4 81675 München / DE | Application number, filing date | 12766780.6 | 13.09.2012 | [2017/45] | WO2012US55034 | Priority number, date | US201161535668P | 16.09.2011 Original published format: US 201161535668 P | [2014/30] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013040141 | Date: | 21.03.2013 | Language: | EN | [2013/12] | Type: | A1 Application with search report | No.: | EP2755993 | Date: | 23.07.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 21.03.2013 takes the place of the publication of the European patent application. | [2014/30] | Type: | B1 Patent specification | No.: | EP2755993 | Date: | 08.11.2017 | Language: | EN | [2017/45] | Search report(s) | International search report - published on: | EP | 21.03.2013 | Classification | IPC: | C07K14/21, A61K38/16, C12N1/15, C12N1/21, C12N5/10, A61K38/00, C07K16/12, C07K16/28, C07K16/30 | [2017/13] | CPC: |
A61K38/164 (EP,US);
A61K47/6829 (US);
A61P35/00 (EP);
C07K14/21 (EP,US);
C07K16/1214 (EP,US);
C07K16/2851 (US);
C07K16/2896 (EP,US);
C07K16/30 (US);
A61K38/00 (EP,US);
C07K2317/34 (EP,US);
C07K2317/56 (US);
C07K2317/622 (EP,US);
|
Former IPC [2014/30] | C07K14/21, A61K38/16, C12N1/15, C12N1/21, C12N5/10 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/30] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | PSEUDOMONAS EXOTOXIN A MIT WENIGER IMMUNOGENEN B-ZELLEPITOPEN | [2014/30] | English: | PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES | [2014/30] | French: | EXOTOXINE A DE PSEUDOMONAS DES ÉPITOPES DE CELLULES B MOINS IMMUNOGÈNES | [2014/30] | Entry into regional phase | 28.02.2014 | National basic fee paid | 28.02.2014 | Designation fee(s) paid | 28.02.2014 | Examination fee paid | Examination procedure | 28.02.2014 | Examination requested [2014/30] | 31.10.2014 | Amendment by applicant (claims and/or description) | 08.05.2015 | Despatch of a communication from the examining division (Time limit: M04) | 18.09.2015 | Reply to a communication from the examining division | 03.02.2016 | Despatch of a communication from the examining division (Time limit: M04) | 13.06.2016 | Reply to a communication from the examining division | 12.09.2016 | Despatch of a communication from the examining division (Time limit: M04) | 18.01.2017 | Reply to a communication from the examining division | 20.03.2017 | Communication of intention to grant the patent | 28.07.2017 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 28.07.2017 | Fee for grant paid | 28.07.2017 | Fee for publishing/printing paid | 25.08.2017 | Information about intention to grant a patent | 25.08.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | EP17195896.0 / EP3301110 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.05.2015 | Opposition(s) | 09.08.2018 | No opposition filed within time limit [2018/42] | Fees paid | Renewal fee | 08.09.2014 | Renewal fee patent year 03 | 28.09.2015 | Renewal fee patent year 04 | 27.09.2016 | Renewal fee patent year 05 | 27.09.2017 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 13.09.2012 | AL | 08.11.2017 | AT | 08.11.2017 | CY | 08.11.2017 | CZ | 08.11.2017 | DK | 08.11.2017 | EE | 08.11.2017 | FI | 08.11.2017 | HR | 08.11.2017 | LT | 08.11.2017 | LV | 08.11.2017 | MC | 08.11.2017 | MK | 08.11.2017 | PT | 08.11.2017 | RO | 08.11.2017 | RS | 08.11.2017 | SE | 08.11.2017 | SI | 08.11.2017 | SK | 08.11.2017 | SM | 08.11.2017 | TR | 08.11.2017 | BG | 08.02.2018 | NO | 08.02.2018 | GR | 09.02.2018 | IS | 08.03.2018 | [2020/34] |
Former [2020/31] | HU | 13.09.2012 | |
AT | 08.11.2017 | ||
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
MK | 08.11.2017 | ||
PT | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2020/28] | HU | 13.09.2012 | |
AT | 08.11.2017 | ||
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
PT | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2020/16] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
TR | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2019/24] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
MC | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/52] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SI | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/40] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
RO | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/37] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
SM | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/35] | AT | 08.11.2017 | |
CY | 08.11.2017 | ||
CZ | 08.11.2017 | ||
DK | 08.11.2017 | ||
EE | 08.11.2017 | ||
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
SK | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/24] | AT | 08.11.2017 | |
FI | 08.11.2017 | ||
HR | 08.11.2017 | ||
LT | 08.11.2017 | ||
LV | 08.11.2017 | ||
RS | 08.11.2017 | ||
SE | 08.11.2017 | ||
BG | 08.02.2018 | ||
NO | 08.02.2018 | ||
GR | 09.02.2018 | ||
IS | 08.03.2018 | ||
Former [2018/22] | FI | 08.11.2017 | |
LT | 08.11.2017 | ||
NO | 08.02.2018 | Cited in | International search | [I]WO2007031741 (CAMBRIDGE ANTIBODY TECH [GB], et al) [I] 1-43 * Whole document, especially tables 1 and 3 *; | [AD]WO2009032954 (US GOV HEALTH & HUMAN SERV [US], et al) [AD] 1-43 * Whole document, especially the claims *; | [X] - "Target specific chimeric toxin associated protein.", Geneseq, (20020813), Database accession no. AAU96810, URL: EBI, XP002688095 [X] 1,2,4-6,22,27,36,37 * the whole document * | [I] - ONDA MASANORI ET AL, "Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20061201), vol. 177, no. 12, ISSN 0022-1767, pages 8822 - 8834, XP002420637 [I] 1-43 * Whole document, especially page 8827 left column * | [I] - M. ONDA ET AL, "Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110405), vol. 108, no. 14, doi:10.1073/pnas.1102746108, ISSN 0027-8424, pages 5742 - 5747, XP055036968 [I] 1-43 * Whole document, especially figure 2 * DOI: http://dx.doi.org/10.1073/pnas.1102746108 | [A] - ROSCOE D M ET AL, "Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (19970601), vol. 27, no. 6, doi:10.1002/EJI.1830270624, ISSN 0014-2980, pages 1459 - 1468, XP000857609 [A] 1-43 * Whole document, especially Figure 4. * DOI: http://dx.doi.org/10.1002/eji.1830270624 | [A] - NAGATA S ET AL, "Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 61, no. 11, doi:10.1016/J.ADDR.2009.07.014, ISSN 0169-409X, (20090930), pages 977 - 985, (20090811), XP026666157 [A] 1-43 * the whole document * DOI: http://dx.doi.org/10.1016/j.addr.2009.07.014 | by applicant | US4450150 | EP0173494 | WO8702671 | GB2188638 | US4816567 | US4892827 | EP0404097 | US5087616 | WO9311161 | US5225539 | US5242824 | EP0239400 | US5449752 | US5512658 | US5545806 | US5569825 | US5585089 | US5602095 | US5608039 | US5639641 | US5693761 | US5714352 | US5747654 | US5821238 | WO9845322 | US5846535 | US5854044 | US5859205 | US5888773 | US5889157 | WO9951643 | US5981726 | US5990296 | US6265150 | US2002197266 | WO03027135 | US6558672 | US7081518 | WO2007016150 | US2007189962 | US7355012 | US7368110 | US7470775 | WO2009032954 | US7521054 | WO2011032022 | - SIEGALL ET AL., J. BIOL. CHERN., (1989), vol. 264, pages 14256 - 14261 | - PAI ET AL., PROC. NAT 'L ACAD. SCI. USA, (1991), vol. 88, pages 3358 - 62 | - KONDO ET AL., BIOL. CHEM., (1988), vol. 263, pages 9470 - 9475 | - WANG J. ET AL., CELL, (1987), vol. 48, pages 129 - 136 | - PASTAN ET AL., BIOCHIM. BIOPHYS. ACIA, (1997), vol. 1333, pages CL - C6 | - DUCKERT ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, (2004), vol. 17, no. 1, pages 107 - 112 | - WADWA ET AL., J. DRUG TARGETING, (1995), vol. 3, page 111 | - JONES ET AL., NATURE, (1986), vol. 321, page 522 | - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534 | - RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323 | - WINTER; MILSTEIN, NATURE, (1991), vol. 349, page 293 | - WESOLOWSKI, MED MICROBIOL IMMUNOL., (2009), vol. 198, no. 3, pages 157 - 74 | - SAERENS ET AL., CURR. OPIN. PHARMACOL., (2008), vol. 8, no. 5, pages 6 00 - 8 | - HANNSEN; DE HAARD, APPL. MICROBIOL. BIOTECHNOL., (2007), vol. 77, no. 1, pages 13 - 22 | - ARNDT ET AL., J. MOL. BIOL., (2001), vol. 312, pages 221 - 228 | - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448 | - HOLT ET AL., TRENDS BIOTECH, (2003), vol. 21, no. 11, pages 484 - 490 | - GHAHROUDI, FEBS LETT., (1997), vol. 414, pages 521 - 526 | - LAUWEREYS ET AL., EMBO J, (1998), vol. 17, pages 3512 - 3520 | - REITER ET AL., J. MOL. BIOL., (1999), vol. 290, pages 685 - 698 | - DAVIES; RIECHMANN, BIOTECHNOLOGY, (2001), vol. 13, pages 475 - 479 | - KOHLER; MILSTEIN, EUR. J. IMMUNOL., (1976), vol. 5, pages 511 - 519 | - HASKARD; ARCHER, J. IMMUNOL. METHODS, (1984), vol. 74, no. 2, pages 361 - 67 | - RODER ET AL., METHODS ENZYMOL., (1986), vol. 121, pages 140 - 67 | - HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 81 | - PEDERSEN ET AL., J. MOL. BIO/., (1994), vol. 235, pages 959 - 973 | - MUFSON ET AL., FRONT. BIOSCI., (2006), vol. 11, pages 337 - 43 | - FRANKEL ET AL., CLIN. CANCER RES., (2000), vol. 6, pages 326 - 334 | - KREITMAN ET AL., AAPS JOURNAL, (2006), vol. 8, no. 3, pages E532 - E551 | - BANKER AND CHALMERS, Pharmaceutics and Pharmacy Practice, J.B. LIPPINCOTT COMPANY, (1982), pages 238 - 250 | - ASHP Handbook on Injectable Drugs, 4th ed.,, (1986), pages 622 - 630 |